| 臺大學術典藏 |
2021-09-01T01:53:41Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; Chen I.-C.; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T01:53:40Z |
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
|
Hsu C.; Tsou H.-H.; Lin S.-J.; Wang M.-C.; Yao M.; Hwang W.-L.; Kao W.-Y.; Chiu C.-F.; Lin S.-F.; Lin J.; Chang C.-S.; Tien H.-F.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
Reply
|
Hsu C.; Chen P.-J.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:25Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; Lin Z.-Z.; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:24Z |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: The role of survivin
|
Ou D.-L.; Lee B.-S.; Lin L.-I.; Liou J.-Y.; Liao S.-C.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity
|
Kuo S.-H.; Yeh K.-H.; Chen L.-T.; Lin C.-W.; Hsu P.-N.; Hsu C.; Wu M.-S.; Tzeng Y.-S.; Tsai H.-J.; Wang H.-P.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:42:18Z |
Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma
|
Ou D.-L.; Shyue S.-K.; Lin L.-I.; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:50Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:49Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; ANN-LII CHENG; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:44Z |
Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges
|
Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:43Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:42Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Chen B.-B.; Hsu C.-Y.; Yu C.-W.; Liang P.-C.; Hsu C.; Hsu C.-H.; ANN-LII CHENG; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; Tan C.-T.; Chen C.-W.; Ou D.-L.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:29Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; Chen C.-H.; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; ANN-LII CHENG; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:25Z |
Development of a PD-L1-expressing orthotopic liver cancer model: Implications for immunotherapy for hepatocellular carcinoma
|
Ou D.-L.; Lin Y.-Y.; Hsu C.-L.; Lin Y.-Y.; Chen C.-W.; Yu J.-S.; Miaw S.-C.; Hsu P.-N.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:23Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:22Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
Lin Z.-Z.; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:21Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-08-24T02:10:06Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; Chen T.W.-W.; TAO-MIN HUANG; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-08-23T03:43:53Z |
Spectrum of cancer patients receiving renal biopsy
|
FAN-CHI CHANG; Chen T.W.-W.; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-08-18T07:39:08Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; JHE-CYUAN GUO; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-18T07:39:05Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; JHE-CYUAN GUO; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-18T07:39:04Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.; JHE-CYUAN GUO; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-16T03:26:41Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
I-CHUN CHEN; Hsu C.; Chen Y.C.; Chien S.F.; Kao H.F.; Chang S.Y.; Hu F.C.; Yeh K.H. |
| 臺大學術典藏 |
2021-08-16T03:26:41Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
I-CHUN CHEN; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; Cheng A.L. |
| 臺大學術典藏 |
2021-08-16T03:26:40Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; I-CHUN CHEN; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
YANG SHIH-HUNG; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:30Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; YANG SHIH-HUNG; Huang S.-M.; Hsu C.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:27Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
YANG SHIH-HUNG; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:24Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
YANG SHIH-HUNG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:23Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; YANG SHIH-HUNG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-12T04:01:22Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; YANG SHIH-HUNG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-11T03:46:53Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:50Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:48Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
